The FDA said patients should monitor the injection site.
The Food and Drug Administration is warning healthcare professionals of possible adverse injection site reactions in patients receiving naltrexone, which is used in outpatient settings for the treatment of alcohol dependence.
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.